$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000157628022000092 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$126.9M	$117.4M
YoY Change	17.37%	23.87%
Cost Of Revenue	$47.12M	$40.50M
YoY Change	40.99%	31.41%
Gross Profit	$79.77M	$76.91M
YoY Change	6.81%	20.24%
Gross Profit Margin	62.86%	65.51%
Selling, General & Admin	$119.3M	$121.5M
YoY Change	19.46%	21.15%
% of Gross Profit	149.57%	157.97%
Research & Development	$106.6M	$100.0M
YoY Change	45.96%	40.93%
% of Gross Profit	133.61%	130.05%
Depreciation & Amortization	$10.17M	$9.100M
YoY Change	66.98%	82.0%
% of Gross Profit	12.75%	11.83%
Operating Expenses	$225.9M	$221.5M
YoY Change	30.65%	29.35%
Operating Profit	-$146.1M	-$144.6M
YoY Change	48.79%	34.78%
Interest Expense	$6.906M	$644.0K
YoY Change	68960.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$119.0K	-$18.39M
YoY Change	-113.25%	9733.69%
Pretax Income	-$139.3M	-$161.9M
YoY Change	92.71%	50.68%
Income Tax	$602.0K	$115.0K
% Of Pretax Income
Net Earnings	-$139.9M	-$162.0M
YoY Change	53.92%	50.66%
Net Earnings / Revenue	-110.28%	-137.98%
Basic Earnings Per Share		-$1.58
Diluted Earnings Per Share	-$1.37	-$1.58
COMMON SHARES
Basic Shares Outstanding	102.4M shares	102.2M shares
Diluted Shares Outstanding		102.3M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.011B	$958.0M
YoY Change	8.41%	-35.53%
Cash & Equivalents	$141.6M	$158.3M
Short-Term Investments	$869.6M	$799.7M
Other Short-Term Assets	$31.51M	$23.57M
YoY Change	-40.61%	7.32%
Inventory	$51.60M	$63.05M
Prepaid Expenses
Receivables	$97.26M	$86.20M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.192B	$1.131B
YoY Change	6.95%	-29.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$167.9M	$168.0M
YoY Change	34.92%	58.26%
Goodwill	$3.290M	$3.290M
YoY Change	0.0%	0.0%
Intangibles	$11.73M	$12.42M
YoY Change	-17.46%	-15.52%
Long-Term Investments	$0.00	$156.7M
YoY Change	-100.0%	-37.36%
Other Assets	$61.45M	$51.73M
YoY Change	0.85%	-15.64%
Total Long-Term Assets	$418.4M	$570.9M
YoY Change	-61.63%	-9.68%
TOTAL ASSETS
Total Short-Term Assets	$1.192B	$1.131B
Total Long-Term Assets	$418.4M	$570.9M
Total Assets	$1.610B	$1.702B
YoY Change	-26.97%	-23.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$68.91M	$40.91M
YoY Change	291.99%	161.01%
Accrued Expenses	$106.9M	$63.37M
YoY Change	136.07%	56.56%
Deferred Revenue	$17.40M	$13.42M
YoY Change	53.66%	83.45%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$193.2M	$175.1M
YoY Change	-0.75%	71.18%
LONG-TERM LIABILITIES
Long-Term Debt	$1.137B	$1.137B
YoY Change	0.23%	0.23%
Other Long-Term Liabilities	$9.179M	$6.988M
YoY Change	133.38%	104.09%
Total Long-Term Liabilities	$9.179M	$6.988M
YoY Change	133.38%	104.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$193.2M	$175.1M
Total Long-Term Liabilities	$9.179M	$6.988M
Total Liabilities	$1.550B	$1.535B
YoY Change	-0.62%	5.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.662B	-$1.522B
YoY Change	64.95%	66.04%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.18M	$166.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.610B	$1.702B
YoY Change	-26.97%	-23.53%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$139.9M	-$162.0M
YoY Change	53.92%	50.66%
Depreciation, Depletion And Amortization	$10.17M	$9.100M
YoY Change	66.98%	82.0%
Cash From Operating Activities	-$90.75M	-$78.16M
YoY Change	17.87%	47.07%
INVESTING ACTIVITIES
Capital Expenditures	$10.00M	-$21.73M
YoY Change	-140.61%	-1.91%
Acquisitions
YoY Change
Other Investing Activities	$80.63M	$63.00M
YoY Change	-133.31%	-349.55%
Cash From Investing Activities	$70.63M	$41.27M
YoY Change	-126.48%	-187.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.318M	-19.31M
YoY Change	-38.68%	247.34%
NET CHANGE
Cash From Operating Activities	-90.75M	-78.16M
Cash From Investing Activities	70.63M	41.27M
Cash From Financing Activities	2.318M	-19.31M
Net Change In Cash	-17.80M	-56.20M
YoY Change	-94.76%	-47.03%
FREE CASH FLOW
Cash From Operating Activities	-$90.75M	-$78.16M
Capital Expenditures	$10.00M	-$21.73M
Free Cash Flow	-$100.8M	-$56.43M
YoY Change	92.41%	82.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	City Area Code CityAreaCode	855
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38683
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3100 Hanover Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	102436169	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158310000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	492202000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	799727000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	440546000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	86200000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97652000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	63047000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	30674000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23565000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	53052000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1130849000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1114126000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	156741000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	698034000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	168007000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124461000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	178747000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	189443000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12417000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14207000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51728000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60938000	usd
CY2022Q3	us-gaap	Assets Assets	1701779000	usd
CY2021Q4	us-gaap	Assets Assets	2204499000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	40911000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17580000	usd
CY2022Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	57423000	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	42496000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63367000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45285000	usd
CY2022Q3	gh	Investments Payable InvestmentsPayable	0	usd
CY2021Q4	gh	Investments Payable InvestmentsPayable	78000000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13423000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11326000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	175124000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	194687000	usd
CY2022Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1136748000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1134821000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216174000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	226053000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6988000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3933000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1535034000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1559494000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102413638	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102413638	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101767446	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101767446	shares
CY2022Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1716075000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1657593000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26852000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4764000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1522479000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1007825000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	166745000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	645005000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1701779000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2204499000	usd
CY2022Q3	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	102054000	usd
CY2021Q3	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	79272000	usd
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	278252000	usd
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	215605000	usd
CY2022Q3	gh	Revenue From Development Services RevenueFromDevelopmentServices	15350000	usd
CY2021Q3	gh	Revenue From Development Services RevenueFromDevelopmentServices	15507000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	44395000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	49940000	usd
CY2022Q3	us-gaap	Revenues Revenues	117404000	usd
CY2021Q3	us-gaap	Revenues Revenues	94779000	usd
	us-gaap	Revenues Revenues	322647000	usd
	us-gaap	Revenues Revenues	265545000	usd
CY2022Q3	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	39434000	usd
CY2021Q3	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	29665000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	104493000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	78142000	usd
CY2022Q3	gh	Cost Of Development Services CostOfDevelopmentServices	1062000	usd
CY2021Q3	gh	Cost Of Development Services CostOfDevelopmentServices	1151000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	4711000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	11348000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100017000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70968000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	267229000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	190200000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	80370000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	50228000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	218405000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	132282000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41121000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50055000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	126068000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	166366000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	262004000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	202067000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	720906000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	578338000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-144600000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-107288000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-398259000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-312793000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1754000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	689000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3919000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3277000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	644000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	644000	usd
	us-gaap	Interest Expense InterestExpense	1933000	usd
	us-gaap	Interest Expense InterestExpense	1934000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18389000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-187000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18059000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-720000	usd
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2021Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-99785000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-161879000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107430000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-514117000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-312170000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	115000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	537000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	289000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-161994000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-107526000	usd
	us-gaap	Profit Loss ProfitLoss	-514654000	usd
	us-gaap	Profit Loss ProfitLoss	-312459000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-161994000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-161994000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-107526000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107526000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-514654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-514654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-314759000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-314759000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.11
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102289000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102289000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101420000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101420000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102065000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102065000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101184000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101184000	shares
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-161994000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-107526000	usd
	us-gaap	Profit Loss ProfitLoss	-514654000	usd
	us-gaap	Profit Loss ProfitLoss	-312459000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2062000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-513000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19348000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2097000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-529000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-113000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2740000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1193000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2591000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-626000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22088000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3290000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-164585000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-108152000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-536742000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-315749000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2300000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-164585000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108152000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-536742000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-318049000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	319087000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	347000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4340000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20639000	usd
CY2022Q3	gh	Adjustments To Additional Paid In Capital Tender Offer Issued AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued	4403000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2591000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-161994000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	166745000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1677000	usd
CY2021Q3	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	13000	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7199000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35016000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-626000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-107526000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	709420000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	645005000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2504000	usd
	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	8000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5742000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6519000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70982000	usd
	gh	Adjustments To Additional Paid In Capital Tender Offer Issued AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued	14235000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22088000	usd
	us-gaap	Profit Loss ProfitLoss	-514654000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	166745000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1298495000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7065000	usd
	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	39000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5401000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	82157000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	124592000	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-2300000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3290000	usd
	us-gaap	Profit Loss ProfitLoss	-312459000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	709420000	usd
	us-gaap	Profit Loss ProfitLoss	-514654000	usd
	us-gaap	Profit Loss ProfitLoss	-312459000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25793000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16181000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	21394000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	17782000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4195000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1845000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	70982000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	124592000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1926000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1922000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3366000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9546000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-13230000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	5261000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
	gh	Fair Value Adjustments Of Noncontrolling Interest Liability FairValueAdjustmentsOfNoncontrollingInterestLiability	-99785000	usd
	gh	Fair Value Adjustments Of Noncontrolling Interest Liability FairValueAdjustmentsOfNoncontrollingInterestLiability	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11431000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7445000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	32375000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2023000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28387000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5758000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4770000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3226000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17752000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6939000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	14927000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10558000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	14034000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10484000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-12993000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	258000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4052000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1233000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-218714000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-132029000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	238601000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	334082000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	398000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	627110000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12750000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	39076000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67460000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50410000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	79189000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	203542000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	53000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	129000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2505000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7065000	usd
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss ContractualReceivablesBeforeAllowanceForCreditLoss	8000000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5742000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5401000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6519000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	82157000	usd
	gh	Payments For Joint Venture Acquisition Financing Activities PaymentsForJointVentureAcquisitionFinancingActivities	177785000	usd
	gh	Payments For Joint Venture Acquisition Financing Activities PaymentsForJointVentureAcquisitionFinancingActivities	0	usd
	gh	Noncash Tender Offer Issued NoncashTenderOfferIssued	-14236000	usd
	gh	Noncash Tender Offer Issued NoncashTenderOfferIssued	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1065000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	784000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-191411000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-70604000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2740000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1193000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-333676000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-284000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	492288000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	832977000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158612000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	832693000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4073000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	171068000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8914000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9589000	usd
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	0	usd
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	346000	usd
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	0	usd
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	238000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158310000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	832370000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	302000	usd
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	323000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158612000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	832693000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. </span></div>The severity of the impact on the Company's business for the remainder of calendar year 2022 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2020Q3	gh	Contractual Receivables Term ContractualReceivablesTerm	P6Y
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	100000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	20800000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	39400000	usd
	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	5300000	usd
CY2022Q3	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	5300000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1000000	usd
CY2021Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1100000	usd
	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	5900000	usd
CY2022Q3	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	0	usd
CY2022Q3	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2022Q3	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
CY2021Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
CY2022Q3	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	4800000	usd
CY2021Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	5900000	usd
CY2022Q3	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2022Q3	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2021Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
CY2022Q3	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q3	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	usd
	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
CY2022Q3	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2021Q3	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5100000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5700000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	246630000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q3	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	400000	usd
	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	2700000	usd
CY2021Q3	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	0	usd
	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	0	usd
CY2022Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	1900000	usd
CY2021Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3200000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	4700000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	17800000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15400000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7700000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8000000	usd
CY2021Q4	gh	Investments Payable InvestmentsPayable	78000000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	179285000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78623000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54824000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	168007000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124461000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	9100000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	5000000	usd
	us-gaap	Depreciation Depreciation	23900000	usd
	us-gaap	Depreciation Depreciation	14600000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20492000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12856000	usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3564000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4223000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10559000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6994000	usd
CY2022Q3	gh	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	7665000	usd
CY2021Q4	gh	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	3332000	usd
CY2022Q3	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	8244000	usd
CY2021Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	4166000	usd
CY2022Q3	gh	Accrued Expenses Property And Equipment Current AccruedExpensesPropertyAndEquipmentCurrent	337000	usd
CY2021Q4	gh	Accrued Expenses Property And Equipment Current AccruedExpensesPropertyAndEquipmentCurrent	5893000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4152000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8354000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7821000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63367000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45285000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2022Q3	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	1067769000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22939000	usd
CY2022Q3	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	1044830000	usd
CY2021Q4	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	1499957000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3594000	usd
CY2021Q4	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	1496365000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-13200000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-13200000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	847927000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	19915000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	108541000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3024000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	956468000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	22939000	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
CY2021Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
CY2022Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6169000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12417000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q3	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6169000	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	15707000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4379000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12607000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4379000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	17497000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	691000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2747000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2219000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1670000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1212000	usd
CY2022Q3	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	3878000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12417000	usd
CY2020Q4	gh	Convertible Debt Hedge Strike Price ConvertibleDebtHedgeStrikePrice	182.60
CY2020Q4	gh	Convertible Debt Hedge Share Price Premium Percentage ConvertibleDebtHedgeSharePricePremiumPercentage	0.75
CY2020Q4	us-gaap	Share Price SharePrice	104.34
CY2020Q4	gh	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges	90000000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	7200000	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	6900000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	21400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	17800000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0395
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0401
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7234000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	30306000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	32806000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	32175000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	27688000	usd
CY2022Q3	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	149636000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	279845000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	43179000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	236666000	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16455349	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13416775	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5231624	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2624974	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.17
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	193014000	usd
	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	488174	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	42.15
	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Connection With The Joint Venture Acquisition Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInConnectionWithTheJointVentureAcquisitionGross	15128	shares
	gh	Share Based Compensation Arrangements By Share Based Payment Award Options Granted In Connection With The Joint Venture Acquisition Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInConnectionWithTheJointVentureAcquisitionWeightedAverageExercisePrice	4.90
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207353	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30581	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	87.94
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6923088	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2890342	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.25
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93798000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2055854	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.01
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	85683000	usd
CY2022Q1	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.66
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	65.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	72.14
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	32900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20639000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35016000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70982000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	124592000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-161994000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-107526000	usd
	us-gaap	Profit Loss ProfitLoss	-514654000	usd
	us-gaap	Profit Loss ProfitLoss	-312459000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-161994000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-161994000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-107526000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107526000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-514654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-514654000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-314759000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-314759000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.11
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102289000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102289000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101420000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101420000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102065000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102065000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101184000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101184000	shares
CY2022Q3	us-gaap	Revenues Revenues	117404000	usd
CY2021Q3	us-gaap	Revenues Revenues	94779000	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16617000	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14751000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15617000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14978000	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Revenues Revenues	322647000	usd
	us-gaap	Revenues Revenues	265545000	usd

Files In Submission

Name	View Source	Status
gh-20220930_def.xml	Edgar Link	unprocessable
0001576280-22-000092-index-headers.html	Edgar Link	pending
0001576280-22-000092-index.html	Edgar Link	pending
0001576280-22-000092.txt	Edgar Link	pending
0001576280-22-000092-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gh-09302022x10qxex311.htm	Edgar Link	pending
gh-09302022x10qxex312.htm	Edgar Link	pending
gh-09302022x10qxex313.htm	Edgar Link	pending
gh-09302022x10qxex321.htm	Edgar Link	pending
gh-09302022x10qxex322.htm	Edgar Link	pending
gh-09302022x10qxex323.htm	Edgar Link	pending
gh-20220930.htm	Edgar Link	pending
gh-20220930.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gh-20220930_cal.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
gh-20220930_pre.xml	Edgar Link	unprocessable
gh-20220930_lab.xml	Edgar Link	unprocessable
gh-20220930_htm.xml	Edgar Link	completed
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2022 Q4 Form 10-Q Financial Statement

#000157628022000092 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2022 Q4 Form 10-Q Financial Statement

#000157628022000092 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh